Pharmacologic treatments for covid-19 patients
Lopinavir-Ritonavir+Interferon beta-1a vs Standard Care
This comparison will not be updated. Last search date 14 Dec, 2022.
Hospitalized patients
Forest plots
(last update: 2022-04-29)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=227
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT04315948 DisCoVeRy Ader F, medRxiv, 2022 Full text Full text Commentary Commentary Commentary |
Mixed |
Lopinavir-Ritonavir Lopinavir-Ritonavir+Interferon beta-1a Hydroxychloroquine Lopinavir-Ritonavir Lopinavir-Ritonavir Lopinavir-Ritonavir+Interferon beta-1a |
Standard care Standard care Standard care Lopinavir-Ritonavir+Interferon beta-1a Hydroxychloroquine Hydroxychloroquine |
RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 32 centers in France and Luxembourg. | N=603 |
Some concerns Details |
|